Hemogenyx Pharmaceuticals PLC Announces Clearance to Initiate Pediatric Enrolment (ACCESS Newswire) - Oct 6, 2025 - "Hemogenyx Pharmaceuticals...s pleased to announce that the Institutional Review Board ('IRB') at MD Anderson Cancer Center ('MD Anderson') has approved an amendment to the clinical protocol of the Company's ongoing Phase I trial of HG-CT-1, its proprietary CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia ('R/R AML'). The approved amendment expands the eligibility criteria for the trial to include children and adolescents with R/R AML..."
Trial status • Acute Myelogenous Leukemia
|